AbCellera Biologics Inc.
ABCL
$3.73
$0.092.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.76% | 5.97% | -12.34% | 27.44% | -78.63% |
| Total Depreciation and Amortization | -81.10% | -81.44% | -2.38% | -298.70% | 416.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 249.17% | 152.37% | -11.07% | 72.78% | -174.20% |
| Change in Net Operating Assets | -216.58% | -109.10% | 138.78% | 957.56% | -180.04% |
| Cash from Operations | -82.10% | -8.14% | 72.30% | 59.21% | -27,147.17% |
| Capital Expenditure | 51.78% | 33.54% | 55.94% | -8.31% | 8.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.45% | -125.55% | -65.64% | 618.93% | 194.42% |
| Cash from Investing | 886.70% | -161.06% | -73.47% | 246.79% | 128.92% |
| Total Debt Issued | 126.91% | 94.25% | 103.85% | 17.28% | -49.25% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -46.30% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.09% | -4,752.46% | 3.78% | 4.32% | 1.08% |
| Cash from Financing | 134.40% | -227.31% | 110.88% | 10.01% | -52.56% |
| Foreign Exchange rate Adjustments | -248.23% | 1,869.77% | 175.54% | -302.25% | 134.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.19% | -370.13% | 130.17% | 175.92% | -195.86% |